Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
Author:
Affiliation:
1. Cognigen Corporation (a Simulations Plus company) Buffalo NY USA
2. Teva Pharmaceutical Industries Ltd. Frazer PA USA
3. Teva Pharmaceutical Industries Ltd. Netanya Israel
Funder
Teva Pharmaceuticals Ltd., Netanya, Israel
Publisher
Wiley
Subject
Clinical Neurology,Neurology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.13845
Reference23 articles.
1. CGRP as the target of new migraine therapies — successful translation from bench to clinic
2. CGRP and the Trigeminal System in Migraine
3. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
4. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
5. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study;European Journal of Neurology;2024-09-04
2. What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?;The Journal of Headache and Pain;2023-12-05
3. Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials;Journal of Pain Research;2023-05
4. Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: A real-world observational study in Japan;Cephalalgia Reports;2023-01-01
5. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions;The Lancet Neurology;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3